Pharma in Brief — USTR Slams Canada Over the Treatment of Pharmaceutical Patents
The USTR Report raises concerns related to IP protection, enforcement and market access in 41 countries. Canada has recently been placed on the Report’s “Watch List” for its mistreatment of pharmaceutical patents. This article explains the reasons for this placement and suggests ways that Canada can reform its existing practices.